IVF Success Rates in Cyprus
“What is the success rate?” is an important question, but it only becomes meaningful when the outcome being measured, the patient group and the denominator are clearly defined. This guide distinguishes between pregnancy, live birth, per-transfer and cumulative outcomes.
- 01The right denominator
- 02By age and oocyte source
- 03Individual probability, not a guarantee
A success rate is not, by itself, a quality score.
The patient population, age distribution, oocyte source, transfer policy and outcome-reporting method of a clinic all affect reported rates. When comparing results, compare the same measures.
Treatment success may be reported as a positive pregnancy test, an ultrasound-confirmed gestational sac, an ongoing pregnancy or a live birth. Rates may also be calculated per cycle started, egg collection, embryo transfer or embryo transferred. The same dataset can produce very different percentages when different denominators are used.
Individual probability should be considered together with factors such as age at oocyte retrieval, ovarian reserve, sperm and fertilisation findings, embryo development, uterine and general health, previous treatment outcomes and whether own or donor oocytes are used.
The same word, “success”, can describe four different outcomes.
Before interpreting a rate, always ask which outcome is being measured and which stage of treatment is used as the denominator.
This means pregnancy hormone has been detected in the blood; on its own, it does not provide sufficient information about the location or ongoing development of the pregnancy.
A measure based on ultrasound findings such as a gestational sac and, depending on the protocol, fetal cardiac activity.
Shows that treatment resulted in a live birth; this rate may be lower than the clinical pregnancy rate.
The combined outcome over a defined period of all fresh and frozen embryo transfers arising from one egg collection.
| Expression | What may the denominator be? | What does it describe? | What should you consider? |
|---|---|---|---|
| “Pregnancy per embryo transfer” | Procedures in which an embryo transfer took place | The probability of pregnancy once transfer has occurred | It does not include cycles that did not reach embryo transfer. |
| “Live birth per cycle started” | All cycles in which medication or monitoring was started | The overall outcome for a person who begins treatment | It includes cancelled cycles and cycles in which no oocytes were obtained. |
| “Birth per embryo transferred” | Number of embryos transferred | The relationship between embryo use and outcome | Single and double embryo transfers can affect comparisons. |
| “Cumulative live birth” | One egg collection and all transfers arising from it | The overall potential of one egg collection | The follow-up period and completion of frozen transfers should be stated. |
“For which age group, oocyte source and time period was this rate calculated, and what denominator was used?” Without this information, a single percentage cannot support a sound comparison.
Success is not the result of a single test or a single technology.
The following factors are not independent of one another. Clinical assessment brings the data together according to the stage of treatment each factor may affect.
Particularly in treatment using a patient’s own oocytes, age at egg collection is closely associated with chromosomal competence and the probability of live birth.
AMH and AFC mainly provide information about the number of oocytes that may be obtained; neither guarantees oocyte quality or pregnancy on its own.
Sperm count, motility, morphology and previous fertilisation outcomes may influence the laboratory strategy.
Fertilisation, cleavage patterns, blastocyst development and, when available, genetic test results are important parts of transfer planning.
The uterine cavity, endometrium, hydrosalpinx, certain systemic conditions and lifestyle factors are assessed.
Patient identification, culture conditions, transfer standardisation and team experience matter at every stage of the treatment pathway.
Outcomes using a patient’s own oocytes and donor oocytes should not be interpreted in the same table as though they are equivalent populations.
In treatment using a patient’s own oocytes, age at egg collection is one of the key determinants. In donor-oocyte treatment, the biological characteristics of the oocyte are largely related to the donor; recipient age remains important for medical pregnancy safety, but success data should be interpreted as a different patient group.
- Outcomes using a patient’s own oocytes should preferably be presented according to age at egg collection.
- Donor-oocyte outcomes should not be mixed with outcomes using a patient’s own oocytes.
- Cycles with and without PGT may not be directly comparable under the same assumptions.
- Fresh and frozen transfer populations may have different characteristics because of selection effects.
- A single-embryo transfer policy should be considered together with the aim of reducing multiple-pregnancy risk.
Statistics provide context; they are not Ventus IVF results or an individual prediction.
The UK regulator HFEA’s 2024 report, published in June 2026, provides a population-level example combining fresh and frozen transfers using patients’ own oocytes. The scope of the data and its preliminary status should always be made clear.
Average live-birth rate per embryo transferred using patients’ own oocytes, averaged across all ages.
Average live-birth rate per embryo transferred for this age group in the same report.
Average live-birth rate per embryo transferred using patients’ own oocytes in the same report.
With high use of single-embryo transfer in 2024, the multiple-birth rate fell to 3.2%.
| Data | Scope | How should it be used? | How should it not be used? |
|---|---|---|---|
| HFEA 2024 averages | A large patient population across licensed UK clinics | As general context showing the importance of age and data definitions | Not as a Ventus IVF clinic result or a guarantee for an individual patient |
| CDC clinic data | Reporting clinics and defined patient groups in the United States | To understand how patient characteristics and procedure types can influence outcomes | Not to choose a clinic solely because it displays the highest percentage |
| Individual prediction tools | Models based on historical data from patients with similar characteristics | For preparing for a medical consultation and discussing a probability range | Not as a diagnosis, medical advice or certain outcome |
| Clinic-specific outcomes | A defined period and clinic patient group | When the time period, age, oocyte source, denominator and outcome definition are transparent | Not as a marketing slogan without methodology |
HFEA notes that 2024 birth outcomes are preliminary and that its new calculation method limits direct comparison with earlier reports. Rates should therefore be presented with their context.
Look for the clearest explanation, not simply the highest percentage.
Ethical and useful communication about success rates makes data limitations, patient selection and safety goals visible alongside strengths.
Questions worth asking
Requesting the following information clearly during a consultation makes comparisons more meaningful.
- Is the outcome live birth, clinical pregnancy or a positive pregnancy test?
- Is the rate calculated per cycle started, egg collection, transfer or embryo transferred?
- What date range and how many cycles were evaluated?
- Are age groups and oocyte sources reported separately?
- How were cancelled cycles and patients who did not reach embryo transfer handled?
- How are single-embryo transfer and multiple-pregnancy rates monitored?
Claims that require caution
The following marketing claims may be misleading when used without methodology.
- “The same success rate at every age”
- “Pregnancy guarantee” or “certain result”
- Presenting a positive-test rate as though it were a live-birth rate
- Presenting donor-oocyte rates as though they were results using patients’ own oocytes
- Selecting only patients who reached transfer and presenting this as the outcome for all treatment starts
- Giving a single percentage without stating patient numbers, time period or denominator
How can your individual probability be discussed more meaningfully?
An individual prognosis should not be reduced to a single number; it is better understood as an assessment that is updated as new information becomes available throughout treatment.
Starting probability
Age, ovarian reserve, cause of infertility, sperm findings and pregnancy and treatment history are assessed. At this stage, the estimated probability may be a broad range.
After ovarian response
The number of developing follicles and oocytes collected allows a more realistic assessment of expected embryo potential.
After fertilisation and embryo development
Normal fertilisation, embryo number, blastocyst development and quality findings provide new information about the probability per transfer.
Transfer and cumulative plan
Alongside the outcome of a single transfer, the overall potential of remaining frozen embryos from the same egg collection is also considered in family-building planning.
Questions patients ask most often
These answers provide general information. Medication, monitoring and travel instructions from your own treatment team take priority.
What does an IVF success rate mean?
Success may be defined as a positive pregnancy test, clinical pregnancy, ongoing pregnancy or live birth. The meaning of the rate depends on clearly stating both the outcome and the denominator.
Why is the live-birth rate lower than the pregnancy rate?
Not every positive test progresses to a clinical pregnancy, and not every clinical pregnancy results in live birth. Live birth is therefore closer to the final treatment outcome but generally a lower measure.
Is a per-transfer rate or a per-cycle rate more meaningful?
They answer different questions. A per-transfer rate includes people who reached embryo transfer, while a rate per cycle started also includes cancelled cycles and cycles that did not reach transfer.
What is the cumulative live-birth rate?
It is the combined probability of live birth from all fresh and frozen embryo transfers arising from one egg collection over a defined period.
Why does age affect IVF success?
Particularly when using a patient’s own oocytes, oocyte age is associated with the likelihood of chromosomal abnormalities in embryos and the chance of live birth. Age is not the only factor, but it is one of the key variables.
Does low AMH mean pregnancy is impossible?
No. AMH is more closely related to ovarian reserve and the expected number of oocytes. Low AMH may influence the treatment plan and the number of oocytes obtained, but it does not by itself mean pregnancy is impossible.
Does high AMH guarantee a high success rate?
No. High AMH may be associated with a greater follicular response, but other factors such as oocyte quality, embryo development, sperm, uterine factors and treatment safety also influence the outcome.
Why are donor-oocyte success rates different?
The biological characteristics of the oocyte are largely related to the donor’s age and selection. Donor-oocyte outcomes should therefore be reported separately from treatment using patients’ own oocytes.
Does PGT-A definitely increase success?
PGT-A can provide information about embryo chromosomal status for selected patients; it does not guarantee a higher live-birth rate for every patient. It should be considered together with age, embryo number, test limitations and treatment goals.
Will a good-quality embryo definitely implant?
No. Morphological quality is important laboratory information, but it cannot guarantee pregnancy because factors such as embryo chromosomal status, uterine conditions and biological interactions also matter.
Does transferring two embryos double the chance of success?
No. Transferring two embryos does not simply double the outcome and may increase the risk of multiple pregnancy. The number of embryos transferred is determined according to age, embryo characteristics, previous outcomes and safety guidance.
Is a clinic better simply because it reports a high success rate?
A high rate alone is not enough. A meaningful comparison requires information about patient selection, age distribution, donor use, denominator, outcome definition, reporting period and multiple-pregnancy policy.
Does an unsuccessful first attempt reduce the chance of success next time?
One unsuccessful cycle does not mean future treatment cannot succeed. The first cycle provides new information about ovarian response, fertilisation and embryo development, which can be used to update the next treatment plan.
Can my personal success rate be calculated exactly?
No. Prediction models and medical assessment can provide a probability range, but biological variability prevents an exact result. The estimate may change as new information becomes available during treatment.
What are the three most important questions to ask about a success rate?
Which outcome is being measured, what is the denominator, and does the data apply to my age and oocyte-source group? Without these three pieces of information, the percentage is incomplete.
Why is a Ventus IVF success rate not shown on this page?
A clinic-specific rate should be published with a defined period, verified patient numbers, age groups, oocyte source, denominator and outcome measure. This page explains the concepts rather than presenting an unverified single marketing percentage.
Key sources used in preparing this guide
These sources support the general medical framework. Each patient’s protocol, monitoring frequency and clinical recommendations may vary according to individual assessment.
Let’s connect the general information to your own treatment plan.
General statistics provide context; your age, oocyte source, AMH/AFC, sperm findings, previous cycle outcomes and planned treatment need to be considered together when discussing your individual probability.